α-Fetoprotein and human chorionic gonadotrophin-β as prognostic markers in neuroendocrine tumour patients
Open Access
- 24 June 2008
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 99 (1), 72-77
- https://doi.org/10.1038/sj.bjc.6604428
Abstract
Serum chromogranin A is the most useful general and prognostic tumour marker available for neuroendocrine tumour (NET) patients. The role of other tumour markers is less clear. In order to determine the diagnostic and prognostic value of serum α-fetoprotein (AFP) and human chorionic gonadotrophin-β (hCGβ) in NETs, a database containing biochemical, histological, and survival data on 360 NET patients was constructed. This data was statistically assessed, using Statistical Package for the Social Sciences, to determine the utility of commonly measured tumour markers with particular emphasis on AFP and hCGβ. α-Fetoprotein and hCGβ were raised in 9.5 and 12.3% of patients respectively and jointly raised in 9.1% of patients in whom it was measured. α-Fetoprotein levels associated strongly and positively with tumour grade, serum CgA and hCGβ levels, and worse survival. Human chorionic gonadotrophin-β levels also associated strongly and positively with serum CgA and AFP levels, and worsening survival. α-Fetoprotein and hCGβ are elevated in high-grade NETs, with a rapidly progressive course and poorer survival. They also correlate with chromogranin-A, which is known to be a marker of tumour burden and to have prognostic value. Thus AFP and hCGβ are clinically important in NETs and when elevated are poor prognostic markers.Keywords
This publication has 17 references indexed in Scilit:
- Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?Journal of Clinical Oncology, 2007
- Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumoursGut, 2006
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- The classification, functions and clinical use of different isoforms of HCGHuman Reproduction Update, 2006
- Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: Why Such Guidelines and How We Went about ItNeuroendocrinology, 2006
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursGut, 2005
- Alpha-fetoprotein gene regulation: lessons from transgenic miceSeminars in Cancer Biology, 1999
- Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the -Subunit of Glycoprotein HormonesJournal of Clinical Endocrinology & Metabolism, 1997
- Alpha‐subunit and human chorionic gonadotropin‐β immunoreactivity in patients with malignant endocrine gastroenteropancreatic tumoursEuropean Journal of Clinical Investigation, 1994
- Neuroendocrine Pancreatic Tumors Clinical Findings in a prospective study of 84 patientsActa Oncologica, 1989